Primary cutaneous marginal zone B-cell lymphoma (PCMZL) was linked to aberrant nuclear B-cell lymphoma 10 (BCL10) expression, but not t(11;18)(Q21;q21) translocation

10-18-2006

"Inhibition of apoptosis seems to play an important role in the pathogenesis of marginal zone lymphoma. Apoptosis regulator BCL10 may show aberrant nuclear localization in some aggressive extracutaneous MALT lymphomas, often in association with a MALT1 gene t(11;18)(q21;q21) translocation. The possible occurrence of this association in PCMZL remains insufficiently explored," scientists in Spain reported.

"The aim of this study was to evaluate BCL10 protein expression pattern and its possible relationship to the presence of t(11:18)(q21;q21) and other MALT1 gene abnormalities in PCMZL and to assess their clinical significance. The study included 42 consecutive PCMZL patients diagnosed on the basis of the World Health Organization/European Organization for the Research and Treatment of Cancer classification criteria," explained F. Gallardo and colleagues, Hospital del Mar.

"BCL10 expression was immunohistochemically evaluated in all cases, whereas t(11;18)(q21;q21) reverse transcriptase polymerase chain reaction amplification was performed on 21 samples. In addition, the presence of other MALT1 gene translocations was explored in 26 samples by interphase fluorescence in situ hybridization using a MALT1 locus-specific probe.

"We observed the presence of aberrant nuclear BCL10 expression in a significant number of PCMZL cases (36%, 15/42). This aberrant expression was significantly related to the development of extracutaneous disease. In contrast, neither the t(11;18)(q21;q21) translocation nor other MALT1 gene translocations could be demonstrated. t(11;18)(q21;q21), strongly linked to extracutaneous MALT lymphomas, does not seem to play a role in PCMZL," noted the investigators.

The researchers concluded, "The participation of other MALT1 gene translocations in PCMZL pathogenesis seems also unlikely."

Gallardo and colleagues published their study in Human Pathology (Aberrant nuclear BCL10 expression and lack of t(11;18)(Q21;q21) in primary cutaneous marginal zone B-cell lymphoma. Hum Pathol, 2006;37(7):867-873).

For additional information, contact F. Gallardo, Hospital del Mar, Dept. of Dermatology, IMAS, Passeig Maritim 25-29, E-08003 Barcelona, Spain.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Related Keywords: MALT1, BCL-10, Apoptosis, Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL)
Related Glossary Terms: NHL, Hodgkin Lymphoma
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Risk of leukemia with multiple sclerosis drug higher than thought
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia (AML)
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Risk of leukemia with multiple sclerosis drug higher than thought
A miR boost enables acute leukemia cells to mature
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Azerra MAA Accepted by EMEA for CLL
Roche's MabThera approved in Europe for CLL
Chronic Myeloid Leukemia (CML)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Scientists Gain Insight Into Blood Cancer's Progression
Some blood-system stem cells reproduce more slowly than expected
Hodgkin Lymphoma
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Hodgkin lymphoma -- new characteristics discovered
Multiple Myeloma
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Green Tea May Negate the Benefits of Velcade
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Myelodysplastic Syndrome (MDS)
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Non-Hodgkin Lymphoma (NHL)
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Testicular Cancer
Second gene linked to familial testicular cancer
Male Infertility Linked to Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer